FDA accepts Praxis PRAX application for epilepsy drug relutrigine

March 30, 2026 4:01 PM

The U.S. Food and Drug Administration has accepted Praxis Precision Medicines Inc.'s (NASDAQ: PRAX) New Drug Application for relutrigine to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found